MSc MD - Soligenix Senior Officer

Soligenix Management Efficiency

The company has return on total asset (ROA) of (0.4514) % which means that it has lost $0.4514 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.398) %, meaning that it created substantial loss on money invested by shareholders. Soligenix's management efficiency ratios could be used to measure how well Soligenix manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.66 in 2024. Return On Capital Employed is likely to rise to -2.01 in 2024. At this time, Soligenix's Total Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 92.2 K in 2024, whereas Non Current Assets Total are likely to drop slightly above 275.5 K in 2024.

Similar Executives

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey. Soligenix operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people. Soligenix (SNGX) is traded on NASDAQ Exchange in USA. It is located in 29 Emmons Drive, Princeton, NJ, United States, 08540 and employs 13 people. Soligenix is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Soligenix Leadership Team

Soligenix Stock Performance Indicators

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Soligenix Stock Analysis